Campus alert status is yellow: For the latest campus alert status, news and resources, visit

Search Close Search
Search Close Search
Page Menu

Medical and Research Technology Research at UMass Medical School.

At UMMS, inquiries on improving biomedical technology that drives the next generation medicine is continually ongoing. These include both 1) Medical Technology and 2) Research/Laboratory Technologies. Browse our inventions by scrolling though the listings below.   


Research Topics on Medical Technology at UMMS includes: 


Browse Our Medical Technology Inventions:




Title: Systems and Methods for Prevention of Pressure Ulcers. UMMS16-69; Patent Pending. 

  • The systems, devices, and methods of this invention provide diagnostic measurements detecting or preventing pressure ulcers. Pressure measurements at body locations are used to determine a diagnostic pressure ulcer value which indicate whether corrective action is needed to prevent pressure ulcer formation. One or more sensor devices can be attached to a patient to measure to transmit data for further processing.

Title: Negative Pressure Amputation Wound Closure Device. UMMS16-33; Patent Pending. 

  • The invention describes systems, devices, and methods to accelerate and reduce medical complications associated with healing of amputation wounds. The devices and methods utilize a compression structure and negative pressure to cause the amputation wound to preferentially close from the deepest portion of the wound to the shallowest portion.

Title: Improving Efficacy of VEGF-Targeted Therapy in Prostate Cancer. UMMS16-02; Patent Pending. 

  • This invention discloses methods to improve the response to VEGF/VEGFR-targeted therapy in patients resistant to bevacizumab and sunitinib. Our critical finding is that inhibition of Rac1 activity using a commercially available compound renders resistant cells sensitive to bevacizumab and sunitinib and can therefore be used as an adjuvant to treat aggressive forms of prostate cancer. 

Back To Top 




  • This invention describes a superior system and method for performing a plurality of robotic surgical interventions, particularly deep brain stimulation and other neurosurgeries, utilizing real-time MRI imaging. 

Title: Adaptive, Multimodal Communication System for Non-Speaking ICU Patients. UMMS15-54; Patent Pending. 

  • This novel communication system is specifically tailored to patients who are restrained and unable to speak permitting communication about topics of ICU relevance. The system consists of 1) a handheld unit, responsive to multiple types of tactile input, which will be accessible to a patient lying in bed; and 2) a tablet displaying visual output and producing synthesized speech output situated above the bed, visible to the patient and to others in the room. The systems most important feature is that both the hardware and software components of the device are completely adaptable to the patients's physical deficits/impairments which vary substantially. Further, the device also produces tactile feedback, e.g. such as producing vibration when an action is initiated and/or completed, a feature shown to benefit those with disabilities. 

Title: Ventricular Shunt Catheter Assembly. UMMS15-36; Patent Pending.  

  • The invention discloses a novel ventricular shunt designed to minimize damage during shunt revision surgery. The novel shunt has an outer catheter sheath that is placed in the first surgery and does not need to be removed even if catheter replacement is needed due to obstruction. It stays as a permanent catheter sheath and creates a permanent access tunnel into the brain ventricle. 

Title: Factor H/Fc Chimeric Molecules as Anti-pathogen Immunoadhesins. UMMS15-30, Patent Pending.  

  • A novel immunotherapeutic approach against drug-resistant pathogens, such as Neisseria gonorrhoeae, comprising administration to a subject a fusion protein linking Factor H to IgG Fc. 

Title: Tet1-Dependent Differentiation of Human Hematopoietic Stem Cell towards NKT And γδ T Cells. UMMS15-18; Patent Pending. 

  • The invention provides methods of producing hematopoietic stem cells (HSCs) with increased differentiation towards natural killer T cells (NKT) and gamma delta T cells (γδ T cells) for cancer immunotherapy. The HSCs are also functionally superior in their capacity to kill tumor cells, as injection of HSCs overexpressing Tet1 eliminates all of the carcinoma stages of neoplasia. 

Title: A Novel Use of Eye Tracking to Improve Radiologists' Diagnostic Accuracy and Training. UMMS15-13; Patent Pending.  

  • This invention provides an eye-tracker and computer software to improve one's ability to observe details in images, particularly radiologic images. The technology is based on the finding that people may believe they have not seen a detail for which they were looking (such as a flaw in a work of art, defect in a machined part, or an abnormality in a tissue sample), when in fact the person may have actually unconsciously detected it. By tracking eye movements the invention provides methods to detect unconscious estimations thereby encouraging the individual to reconsider the initial estimation that the detail was not observed. 

Title: Broadly Borreliacidal Human Monoclonal Antibodies to OspA and their Uses. UMMS15-03; Patent Pending. 

Back To Top 




  • Invention encompasses a new strategy to combat drug-resistant gonorrhea. This technology manipulates the lipooligosacchride capping of gonococci, thereby decreasing it’s fitness and virulence. By interrupting the sialic acid mediated pathogenesis that contributes to drug-resistance, this intervention can render gonorrhoeae sensitive to killing by the innate immunity system. 

Title: SURGICAL FORCEPS ["Design" Patent]. UMMS14-54; Patent US D762,302 S, US D797,284 S.

Title: Surgical Forceps Handle. UMMS14-52; Patent Pending. 

  • The present invention describes forceps having a geometry suitable for precise grasping and manipulation, designed to reduce fatigue in the surgeon and improve surgical outcomes. The forceps use contoured arms having generally rounded surfaces along their longitudinal length. This shape enables the surgeon to easily rotate the forceps to different angles to reduce the need to hold the handle differently. This enables rotation of the forceps within a body cavity without a substantial change of arm position and viewing angle. The contoured surface provides an increase in the grasped surface area thereby increasing the amount of functional contact at many angles.

Title: Human Antibodies Against Rabies and Uses Thereof. UMMS14-48; Patent Pending. 

  • New neutralizing monoclonal antibodies for rabies RAB2 and RAB3. Can be used together or in combination with RAB1, these antibodies have demonstrated superior performance in the treatment of rabies in comparison to other individually tested antibodies and will cover variety of zootonic strains. 

Title: Hyperspectral Imaging for Assessment and Prediction of Thermal Burn Injury. UMMS14-42; Patent Pending. 

  • This innovation addresses the fundamental need to assess early maximal burn depths in burn patients. Early and reliable differentiation between superficial and deep dermal burns is critical for optimizing surgical and resuscitation care. By creating/utilizing a spectral signature of skin, this technology uses non-visible and non-insvasive light to quantify oxy- and deoxy-hemolglobin levels, which can be used to predict thermal exposure. 

Title: Method and System for Reducing Irritability and Cardio-Respiratory Instability in Children. UMMS14-39; Patent Pending. 

  • This invention provides a system to reduce irritability in infants suffering from neonatal abstinence syndrome (NAS) or colic by assessing physiological measurements (e.g. heart rate, respiration rate) from the infant, determining the level of irritability and applying a stochastic stimulation, vibro-tactile or subsensory, via mattress, car-seat, etc. This tool can be used to alleviate drug withdrawal, reduce hospitalization, and improve outcomes in NAS or infants exhibiting colic. 

Title: A New Medical Use of Gadoxetate Disodium to Evaluate Cystic Duct Patency Using CT Scan. UMMS14-33; Patent Pending. 

  • A method of diagnosing a condition in a patient experiencing cholecystitis that uses gadoxeate disodium as a contrast agent for making images such as CT scans of the biliary tree and related anatomical structures. The method uses x-ray radiation generated with excitation voltages in the range of 70 KV to 140 KV. The x-ray radiation is preferably filtered to suppress or practically remove x-rays having energy lower than 50.2 KeV. 

Title: REBISS Score and REBISS Score Calculator. UMMS14-32; Patent Pending. 

  • To prevent misdiagnosis, this technology discloses a clinical scoring system that effectively and efficiently utilizes a number of different data sources to determine a diagnosis of patient conditions. The score is compared to a spectrum of scores in order to identify between disorders, such as Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBSd) or gastroesophageal reflux disease (GERD) and functional dyspepsia for which there are currently no validated scoring systems.

Title: A New Tool for Studying Heterogeneity of Treatment Effects in Longitudinal Translational Research. UMMS14-29; Patent Pending. 

  • The invention generally relates to data analysis. More specifically, the invention relates to analyzing variation in data resulting from clinical trials or observational studies. The invention describes a computer-implemented method for visualizing trajectory pattern recognition of longitudinal data that improves the accuracy and stability of identified patterns, including the structure of high-dimensional (HD) data with missing values.

Title: iSERF: Intelligent Search, Relation Extraction and Research for Functional Biology. UMMS14-25; Patent Pending.

  • The present invention relates generally to identifying relationships between items. Certain embodiments of the present invention are configurable to identify the probability that a certain event will occur by identifying relationships between items. Certain embodiments of the present invention provide an improved supervised machine learning system.

Title: Improved Microbiopsy Device. UMMS14-14; Patent Pending. 

  • This invention relates to an improved microbiopsy needle tip. The improvement is attributable to the presence of one or more combinations of features, including the use of a Franseen-type needle cutting tip, the provision of a "step-out" in which the collection portion of the biopsy device has a larger diameter than the procuring portion of the device, frictional force on the core of tissue exerted by the distal portion of the needle, which force is provided by the diameter of the distal collection portion of the device having substantially the same diameter as that of the procured core of tissue, the mechanical effects of scaling the needle to small dimensions; and the use of a needle that can be curved to as to sample multiple biopsy sites in close proximity without retracting the needle from the patient.

Title: Method and Application for Vascular Phantoms. UMMS14-11; Patent Pending. 

  • This invention provides a novel method of imaging intracranial atherosclerotic disease (ICAD) by creating a 3D vascular phantom based on imaging data of vasculature of a subject. This technology is non-invasive thereby overcoming the significant risk of morbidity and mortality due to catheter angiography, the current gold standard for imaging ICAD. Further, unlike catheter angiography this technology can provide characteristics of the atherosclerotic plaque, vessel wall and information regarding the underlying etiology.

Back To Top



Title: System and Method for Using Somatic Movement to Improve Prediction and Prevention of Infant Apnea. UMMS13-75; Patent Pending.

  • The present invention relates to methods and systems for inhibiting apneic and hypoxic events. More specifically, the present invention provides methods for monitoring physiological signals of a patient, predicting the occurrence of a life-threatening event such as apnea or hypoxia, and initiating a stimulus to lessen the severity of, or even prevent, the occurrence of the life-threatening event.

Title: Anti-fracCRP Hybridomas and Monoclonal Antibodies. UMMS13-71; Patent Pending. 

  • This invention provides antibodies and antibody fragments that bind to human fractional C-Reactive Protein (fracCRP), kits and assays using these antibodies and antibody fragments to diagnose low to moderate risk for Acute Coronary Syndrome (ACS). This invention is based on two clinical studies (one prospective, one retrospective) that measured fracCRP, Troponin I (TnI), and the fracCRPxTnI metric on 210 patients (105 each with final diagnoses of ACS negative or ACS positive). Overall, the method demonstrated strong diagnostic rule-in value for these patients on arrival, with a specificity of 96.2%, positive predictive value of 91.7%, sensitivity of 41.9%, and negative predictive value of 62.3%. 

Title: Compositions and Methods for Recruitment and Activation of Macrophages in Injured Tissues and in Implanted Biomaterials Used for Tissue Engineering. UMMS13-62; Patent Pending. 

  • The present invention is related to the field of wound healing and regeneration and repair of injured internal tissues and tissue engineering by synthetic implants and implants of natural origin. In particular, the present invention provides compositions and methods comprising molecules (such as nanoparticles) with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue, and rapid localized recruitment and activation of macrophages that promote regeneration and repair of a wide variety of internal tissues and organs injured as a result of various types of trauma as well as of tissues and organs treated with biomaterials. 

Title: Chemical Exchange Saturation Transfer Angiography (angioCEST). UMMS13-56; Patent Pending. 

  • The invention provides a novel approach for effective ex vivo and in vivo imaging of blood and establishes the feasibility of blood as an effective agent for Chemical Exchange Transfer Saturation (CEST). The method of the invention is based on the measurement of the labile protons that are associated with various amino acids, proteins, peptides and other molecules that are naturally present in blood. These components are not detectable with currently available clinical MRI sequences, but generate a clear signal by using CEST. MR imaging of blood in vivo remains a major challenge in part because blood flow affects the intensity of MR images in many nonlinear ways that depend both on details of the particular imaging technique and on blood vessel and flow geometry. 

Title: Synchronization of Patient Motion Detection Equipment with Medical Imaging Systems Using a Short Encoded Pulse Sequence Inserted Into a Patient's Electrocardiography (ECG) Gated Input Signal During a List-Mode Image Acquisition. UMMS13-49; Patent Pending.  

  • The present invention provides an improved system to correct for patient motion during imaging modalities such as PET and SPECT. Uniquely, this system acquires multiple physiological signals (EKG signals, tomography signals, gross-body motion signals, respiratory motion signals, voluntary motion signals, involuntary motion signals), using a single data channel.  

Title: Construction of a Trifunctional and Completely Clearable Specific Targeting Agent. UMMS13-45; Patent Pending.

  • This invention provides a novel targeted delivery vehicle designed for enhanced clearing efficiency and reduced non-specific background. The invention discloses a unique pretargeting approach involving a trifunctional targeting construct and related compositions and methods that are useful in therapeutics and diagnosis (including imaging) of various biological and/or pathological conditions and diseases. The trifunctional targeting construct of the invention enables a much enhanced clearing mechanism and significantly reduced non-specific background via the completely clearable antibody construct. 

Title: A Novel Biological Imaging Probes: Cascade Sensitization of Tri-doped -NaYF4:Nd,Yb,Er(Tm)/NaYF4 Core/Shell Colloidal Nanoparticles with a Biocompatiable 800 nm Excited Upconverting Luminescence. UMMS13-41; Patent Pending. 

  • The invention provides novel upconverting luminescence materials (e.g., UCNPs) and methods that have constitutional excitation engineered to optimize at about 800 nm, which is not only well away from peak absorption of water, but also is ideally situated at a local minimum of water absorption. A unique class of cascade sensitized tri-doped UCNPs with a biocompatiable 800 nm excitable property are disclosed, for example, tri-doped P-NaYF :Nd,Yb,Er(Tm)/NaYF UCNPs, which employ Nd3+ as 800 nm photon sensitizer and Yb3+ as bridging ions, affording strong green or blue upconversion emissions without photobleaching. 

Back To Top



Title: POD: Pressurized Oxygen Delivery System. UMMS12-76; Patent Pending. 

  • The present invention discloses a negative pressure wound treatment system that delivers oxygen into the tissue in conjunction with the application of negative pressure thereby facilitation wound healing. 

Title: FACETTED JEWEL BEARINGS. UMMS12-69; Patent 9,678,478.

  • The invention provides bearing systems characterized by single point contact with each jewel segment and a spring-loaded assembly with protection from radial and thrust forces. An important feature of these jewel bearings is that they are self- lubricating, i.e., no oil or grease lubricants are needed. This can be a major advantage in medical and precision equipment. A secondary important feature is the reduced friction and effective heat-dissipation due to the unique design of the invention with significant reduction in contact surfaces and friction, which significantly prolong the lifespan of the bearings. 


  • The invention provides novel surface coatings for metallic implants to prevent periprosthetic infections after orthopedic surgery. To achieve optimal anti-fouling and bactericidial effects of commercial metallic implants, the invention has surface polymer brushes with tightly controlled yet tunable molecular weights (thickness of coating), low-fouling side chain densities and the conformational freedom needed to be grafted from the surface. By employing significantly improved surface-initiated polymerization of low-fouling, zwitterionic polymer brushes and higher-density covalent presentation of antibiotics (e.g. vancomycin) anti-infection outcomes are optimized. 

Title: Apparatus and Method for X-Ray Contrast Imaging. UMMS12-39; Patent Pending. 

  • The invention pertains to an apparatus and method for x-ray phase contrast imaging that uses a scanning interferometer for the x-ray source, source grating, phase grating and detector grating, with the object being imaged stationary.  Importantly, the apparatus and method does not require movement of the phase or detector grating relative to each other, often referred to as phase-stepping. 


  • This novel technology provides a new and improved system for properly orienting orthopedic implants within a patient. Specifically, the invention provides an electronic surgical guidance system that enables proper orientation of a surgical instrument and acetabular component within the pelvis during implantation. Feeback signals from the processor assist the surgeon in properly orienting the instrument relative to a user-defined acceptable range.

Title: Hyperspectral Imaging for Early Detection of Oxygenation and Perfusion Changes in Irradiated Skin. UMMS12-20; Patent Pending.

  • The invention is based on the discovery of hyperspectral imaging-based methods that enable effective, efficient and non-invasive detection and characterization of ionizing radiation exposure in tissue. Methods of the invention allow for complete visualization and quantification of oxygenation and perfusion changes in irradiated skin. The invention enables rapid identification of individuals exposed to ionizing radiation after a radiological attack or accident. Methods of the invention can offer quantitative metrics to identify people exposed to higher doses of ionizing radiation well before the appearance of any dermal injury and permit appropriate triage to healthcare facilities. 

Title: Anterior Cervical Surgical Navigation Reference Array Clamp. UMMS12-19; Patent Pending.  

  • This invention provides an apparatus that connects an imaging treatment guidance system (ITGS) to a fixed location in a patient. Specifically disclosed are systems and methods for providing fixation of a navigation array adjacent to, or in conjunction with anterior spine surgery. 


  • The invention provides novel biocompatible upconversion nanoparticles (UCNP) comprising a core of cubic nanocrystals (e.g., comprising α-Na Lna, Lnb Lnc F4) and an epitaxial shell (e.g., formed from CaF2; wherein Lnb is Yb). The disclosed nanoparticles lack the toxicity of traditional UCNPs and are synthesized in a single reactor vessel making them more amenable to large-scale production. Further provided are methods of whole body imaging and photochemical methods using the disclosed nanoparticles. 


  • This technology discloses polymer conjugated gold nanoparticles with increased stability and biocompatibility for use in imaging, diagnostics, and drug delivery. 

Title: LUCIFERIN AMIDES. UMMS12-04; Patent 9,370,588, US9,814,787B2. 

  • This technology discloses luciferin amides (e.g., amides derived from firefly luciferin and their analogs) and imaging methods to detect fatty acid amide hydrolase (FAAH) activity in vitro, in live cells, and in vivo. The compounds and methods described are more sensitive and faster than conventional coumarin-based FAAH assays.  These assays may be used to identify therapeutic targets for conditions involving inflammation. 

Back To Top 




  • This patented technology provides prophylactic DNA constructs that encode a recombinant HIV-1 gp120 envelope peptide, in which either the V1/V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3 sequence each of which is from a different viral isolate. These constructs generate a more broadly reactive neutralizing antibody than conventional gp120 or V3 DNA or polypeptide immunogens. 


  • This patented technology discloses cellulose and sulfated cellulose fibrous meshes exhibiting robust structural and mechanical integrity in water for use as bone tissue scaffolds. Also, provided are methods of fabrication using a combination of electrospinning, thermal-mechanical annealing and chemical modifications.

Title: Specifications for Operating Room Hand Hygiene and Surgical Scrub Reminder System. UMMS11-34; Patent 8,633,816.  

  • This technology involves a system and method for monitoring personal protection items of a healthcare worker (gloves, gown, mask and respirator), using a user badge which stores data representing items worn by a worker, wirelessly communicating with the badge before the worker enters a patient zone (such as a patient room, bed area or exam table area), to see whether the worker has the required items. Patient beacons, located near patient room doors, near beds and other locations, store data representing the items required by workers who come in contact with, or close proximity to a patient, and wirelessly communicate with the badge. The patient beacon data can be set for the requirement of the patient, based on patient condition. 


  • This patented technology provides a system for recording magnetic resonance images with reduced relaxation-related artifacts. This improves upon conventional methods for acquiring MRI images of in vivo tissue by augmenting the procedures for eliminating artifacts caused by motion and the spin of the magnetic resonance-active nuclei. Specifically, to eliminate such spin the delay time is defined by N*T1, where N is a numerical value greater than or equal to 5 and T1 is the characteristic time constant for decay of spins back to the equilibrium longitudinal state. 


  • This patented invention provides novel biodegradable and biocompatible polymers and hydrogels useful for controlled drug delivery and tissue engineering scaffolds. Specifically, the invention provides versatile, cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted "click" chemistry) with well-defined functionalities. 

Title: TOMOSYNTHESIS IMAGING. UMMS11-05; Patent 8,817,947 

  • This patented technology discloses a system for providing higher quality radiographic, stereoscopic and tomographic images with reduced x-ray dose and operating time to improve patient care. The apparatus includes a high-fluence rate x-ray source and a plurality of satellite x-ray sources operating at lower fluence rate than the high-fluence rate source. A controller controls the operation and locations of the sources, and the operation of a detector. The method provides procedures in which the operation of the high-fluence source and the satellite sources are individually controlled as to location and orientation relative to the object of interest. In some operations, one satellite source may be operating while another satellite source may be repositioning. 

Back To Top



Title: ANTI-SOD1 ANTIBODIES AND USES THEREOF. UMMS10-69; Patent 9,109,037.

  • This invention discloses a panel of newly discovered human monoclonal antibodies against human SOD1 protein.  There are two types of SOD1 antibodies available: 1) one that binds to all forms of SOD1 and 2) one that binds to the misfolded form of SOD1. Mutated SOD1 is associated with 20% of inheritable forms of Amyotrophic Lateral Sclerosis (ALS) and blocking its function is protective. These monoclonal antibodies present a unique therapeutic opportunity to treat ALS with an immunologically targeted approach. 


  • This invention is a new device that enables wound closure from injury or surgery without the use of traditional sutures or staples that cause additional swelling and tissue damage. The new method specifically applies pressure to wound edges while simultaneously removing wound fluids. Using this device in closures promotes higher rates of healing and prevents repetitive replacement of wound filters. 

Title: SULFONATE COMPOUNDS. UMMS10-48; Patent 9,329,185.

  • This invention provides a new chemically-stable platform for delivering hydrophobic molecules in to cell cytoplasm. Sulfonates are used to impart water-solubility to hydrophobic molecules but does not readily cross cellular membrane to access cellular compartments. Thus, the TFA-labile sulfonate protection group helps to overcome the difficulty in delivering hydrophobic molecules to the intracellular environment. Currently existing protection molecules are complicated and expensive to produce while it also requires additional steps to remove its byproducts after TFA mediated deprotection. This new invention TFMB sulfonate esters are unique because they are 1) stable to nucleophilic attack (e.g. sodium iodide and piperidine), 2) synthesized in one step from commercially-available materials, and 3) easily removable with pig liver esterase (~2min). This new UMass Medical School sulfate protection group provides new opportunities for research molecule delivery of hydrophobic drugs to mammalian cells.


  • The present invention improves upon previously described yeast-based microencapsulation methodologies, in particular, by providing for the incorporation of nanoparticles into and/or onto yeast cell wall particles (YCWPs), for example, yeast glucan particles (microparticles) (YGPs). The improved technologies provide for delivery of nanoparticles, the nanoparticles themselves having utility in biomedical applications, or the nanoparticles imparting one or more functionalities of use in various biomedical, e.g., drug delivery applications. 


  • This patented technology discloses pharmaceutical compositions consisting of L-argnine, tetrahydrobiopterin, and ascorbate to treat diseases of oxidative stress and improve the therapeutic properties of stem cells. 

Back To Top




  • This patented technology describes an imaging apparatus with improved blur compensation. Blur due to finite detector resolution in various imaging modalities is a significant problem. Specifically, this invention provides an image reconstruction method using an iterative reconstruction method and computing a projection used in the reconstructing by summing ray increments between neighboring planes (P0, P1, P2, . . .) parallel with a detector face (42) with stationary incremental blurring associated with each ray increment computed based on a distance between the neighboring parallel planes. A non-stationary blurring kernel may also be convolved at a plane closest to the detector face to generate a projection incorporating shift-variant blurring.

Title: BONE FIXTURE ASSEMBLY. UMMS09-49; Patent 8,690,927US9,566,098B2.

  • The present invention provides a screw and plate assembly for sternal fixation. This technology provides an improvement over steel wire fixation, the method currently used for sternal fixation. Specifically, this technology decreases unwanted loosening and failure of the fixation system, a problem common in osteoporotic or lower-density bones.

Back To Top 



Title: Co-evolved Protease Substrate Cleavage Site Mutations Enhance Protease Inhibitor Resistance. UMMS08-59; Patent Pending.  

  • This new invention predicates on the finding that drug resistance in HIV arises from evolution of HIV proteases and it’s associated substrates, and discloses mutation patterns of both proteases and substrates that can be used to predict the efficacy of particular therapy in HIV patients. Understanding these mutational combinations will greatly change the approach to optimizing a patient-centered approach to managing HIV therapy. 


  • This invention builds on the existing non invasive spectroscopic sensor that can detect information from tissues of different thicknesses to aid diagnoses. This invention uses a mathematical approach to calculate capillary SO2, pO2, pH, pCO2, and temperature. The calibration equation for all parameters uses PCA Loading Correction factor to account for subject-to-subject variation that has been used to determine the calibration equation.

Title: HIV-1 Protease Inhibitors: Part 6. UMMS08-41.

  • This invention provides new therapeutic agents to treat HIV using protease inhibitors that are less prone to resistance stemming from drug resistant mutations. Using computational and organic chemistry techniques, the inventors designed these new molecules by carefully considering nature of the HIV protease and it’s ability to detect substrates. This invention contains several sets of HIV protease inhibitors and unique drug combinations that have not yet been previously tested.

Title: SPECTROSCOPIC SENSORS. UMMS08-39; Patent 9,095,291. 

  • This technology is a miniature sensor optimized to collect spectra from the tissue of living subjects. The device accommodates tissues of different thicknesses with just a single sensor. The devices are made of solid state materials that are easy and inexpensive to manufacture. The broad spectrum of readings can detect oxygen tension, pH, hematocrit and potentially more parameters.

Title: Detection of Human Immunodeficiency Virus. UMMS08-36; Patent Pending. 

  • This new PCR based assay can detect cells that have been recently infected by HIV, even those that may not typically be detectable while the patient is under aggressive antiretroviral therapy. In peripheral blood lymphocytes, this method detects circular viral DNA in individuals infected with HIV. This detection method has been found effective even when plasma viral RNA levels are undetectable under conventional HIV RNA-PCR testing. Research on this method also revealed that the currently implemented treatment with antiretroviral agents does not completely abolish the viral infection, providing an opportunity for further innovation in HIV management. 

Title: sST2 Dengue Virus Diagnostic. UMMS08-12; Patent Pending.

  • This invention uses interleukin-receptor like 1 protein (sST2) level to diagnose Dengue fever, infection with Dengue virus. Clinical symptoms of dengue infection are difficult to recognize and most individuals are asymptomatic or have only mild fever. This new technology addresses the need for a more effective diagnostic tool, capitalizing on the understanding that sST2 levels are elevated with in dengue virus infection when compared to uninfected patients. sST2 is further elevated during secondary infection, so this marker may serve to identify severity of infection. 


  • This invention discloses a new method for delivery of nucleic acids, including agents for gene silencing (e.g. siRNAs). This new system is developed with exterior of yeast cell wall particle (YCWP) and interior comprising multilayer nanoparticle core with a payload complex. Using this technology, inventors have effectively shown siRNA can be delivered effectively in macrophages. 


 Back To Top

Research Topics on Research Technology at UMMS includes:

Browse Our Research/Laboratory Inventions:




Title: CARDS: CRISPR Arrayed Repeat Detection System / Part II. UMMS16-41; Patent Pending. 

  • This invention provides a means to resolve the 3-D genome in live cells by disclosing a novel CRISPR-based system in which as many as six different genomic loci can be labeling, each in a distinctive color, in live cells. This technology, called "CRISPRainbow" is far more expansive that fluorescence in situ hybridization (FISH) conducted on fixed cells. The invention further discloses methods to track by real-time fluorescence microscopy the assembly dynamics and target residence lifetimes of CRISPR machinery in live cells. 

Back To Top



Title: Nucleic Acid-guided, Thermostable Restriction Enzyme for DNA and RNA. UMMS15-41.

  • Our invention is a method for the creation of a thermostable, programmable restriction enzyme that can be used to cleave ssRNA, ssDNA, dsRNA, or dsDNA at a specific site determined by the sequence of the small DNA guide bound to Thermus thermophilus Argonaute (TtAgo) protein. This invention is a method that can be used as a molecular biology research tool for cloning and/ manipulating DNA or RNA for research use. 

Title: Transgenic Expression of DnaseI in vivo Delivered by an Adeno-associated Virus Vector. UMMS15-38; Patent Pending.

  • This invention uses AAV therapy to deliver an important enzyme, DNaseI, for cyctic fibrosis (CF) treatment. Traditional clinical methods of DnaseI delivery use solely nebulizers, which limit the delivery of the enzyme to the lung. With this new quality-controlled AAV vector for delivery, DnaseI can now be delivered locally to other organ systems affected by CF for more comprehensive disease management. 

Title: In Vivo Rechargeable Near Infrared Emitting Mesoporous Persistent Luminescence Nanocomposites. UMMS15-20; Patent Pending.  

  • The invention provides methods to produce novel mesoporous persistent luminescece silica nanoparticles that are uniform and homogeneous for optical imaging applications. 

Title: Monoclonal Antibodies Specific for mCherry. UMMS15-10. 

Title: Monoclonal Antibodies that bind Citrullinated Human Fibrinogen. UMMS15-07. 

Back To Top 


Title: Monoclonal Antibodies Specific for Streptavidin. UMMS14-67.

Title: Surface Mineralization of Metal Alloys Grafted With Zwitterionic Polymer Brushes. UMMS14-36; Patent Pending. 

  • The invention provides a novel approach to hydrogels with predictable degradation/gelling kinetics, which is useful for many biomedical applications where appropriate gelling kinetics and the timely disintegration of the hydrogel (e.g., drug delivery, guided tissue regeneration) is required. Precisely controlling hydrogel degradation over a broad range in a predictable manner is achieved via a simple but versatile hydrogel platform that allows formulation of hydrogels with predictable disintegration time from within 2 days to >250 days yet comparable macroscopic physical properties. 

Title: Surface Mineralization of Metal Alloys Grafted With Zwitterionic Polymer Brushes. UMMS14-35; Patent Pending.

  • The invention provides novel compositions and methods of surface mineralization for metallic or ceramic implants and devices and the resulting enhancement of properties and performance in skeletal tissue engineering, orthopedic applications and dental care. The novel approach utilizes zwitterionic brushes (e.g., of poly(sulfobetaine methacrylate) or pSBMA) covalently grafted on the surface of titanium or its alloy substrates (e.g., Ti6A14V) to promote surface-mineralization of hydroxyapatite with enhanced surface mineral coverage and mineral- substrate interfacial adhesion. The zwitterionic surface brushes, capable of attracting both cationic and anionic precursor ions during hydroxyapatite-mineralization, significantly increase the surface mineral coverage and significantly reinforce the attachment of the surface apatite crystals on the titanium alloy substrate which withstood supersonication treatment. 

Title: Expansion of Human Adipocyte White and "Brite/Beige" Progenitors through Angiogenic Expansion of their Vascular Niche. UMMS14-26; Patent Pending. 

  • This invention relates to methods of making human adipose capillary progenitor cells (HACAPS), which are capable of giving rise to either white or "Brown-on-white" (Brite) adipose cells, and enriched populations thereof, for reconstructive and metabolic therapy, and for drug discovery. Further, methods of treating subjects by administering HACAPS are provided. 

Title: A Versatile Microplate Design for High Performance Spectroscopic Applications. UMMS14-19; Patent Pending.

  • This novel technology describes a microplate for use in high-throughput determinations of protein stability, protein-DNA/RNA binding, and protein-protein associations. The disclosed invention overcomes the limitations of other microplate designs including meniscus formation, variable path length for each well, and compatibility with use in the UV and far-UV region. The invention uses two optical flats, which for example can be quartz glass, and a spacer having a plurality of holes defined in the spacer to make optical measurements. 

Title: Alkylated Amphiphilic Polymer Networks for Bioactive Lipid Delivery. UMMS14-16; Patent Pending. 

  • The invention provides unique amphiphilic polymers may be employed as controlled delivery vehicles or tissue engineering scaffolds wherein the delivery of lipophilic or amphiphilic bioactive molecules can be achieved. An amphiphilic biodegradable polymer platform is disclosed herein for the stable encapsulation and sustained release of biomolecules, such as phospholipid spingosine 1-phosphate (SIP) which can be used to promote angiogenesis alone or in conjunction with VEGF.

Title: Cas9 Effector-mediated Regulation of Transcription and Differentiation in Human Pluripotent Stem Cells. UMMS14-12; Patent Pending. 

  • This invention provides novel methods of and systems for modifying the transcriptional regulation of stem or progenitor cells to promote their differentiation or reprogramming of somatic cells. Further, the labeling and editing of human genomic loci in live cells with three orthogonal CRISPR/Cas9 components allow multicolor detection of genomic loci with high spatial resolution, which provides an avenue for barcoding elements of the human genome in the living state. This technology provides a much needed system that can be used to promote differentiation of a stem, progenitor or precursor cell population and can be used in a directed approach to identify genes related to cell differentiation down desired lineage pathways.

Back To Top



Title: Self-anchoring Biodegradable Polymeric Implants. UMMS13-76; Patent Pending. 

  • This invention provides novel synthetic bone grafting materials or tissue engineering scaffolds with desired structural and biological properties (e.g., well-controlled macroporosities, spatially defined biological microenvironment, good handling characteristics, self-anchoring capabilities and shape memory properties) and methods of their applications in vivo.  Specifically, the invention relates to polymer scaffolds and composites of biodegradable amphiphilic polymers and inorganic minerals as well as methods for their preparation.

Title: INHIBITIONOFFGFSIGNALING. UMMS13-66; Patent 7,968,527.  

  • The technology discloses methods for inhibiting FGF signaling, a pathway that plays a role in embryogenesis, angiogenesis and cancer. The method comprises contacting the FGF-responsive cell with an exogenous Sulf1-treated heparin compound resulting in reduced cellular proliferation, cellular migration, and angiogenesis. In stem cells, FGF inhibition supresses mesoderm formation and, thereafter, redirects cellular differentiation to ectoderm.

Title: BCR Adapter lgM (BCRAM) for the BCR/TLR Delivery of Autoantigens to Polyclonal Murine and Human B Cell Populations. UMMS13-65; Patent Pending.

  • This technology provides a model for autoantigen activation of B cells that can be used to research and treat the development/progression of autoimmune diseases, such as systemic lupus erythematosus (SLE).  This novel research tool enables the identification of suitable drug targets and provides methods for production of autoantigens.  Specifically, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by Toll-like receptor activation. 


  • The present invention discloses a transcription activator-like effector-based strategy, termed “TALEColor”, for labeling specific repetitive DNA sequences in human chromosomes. TALEs were custom designed for human telomeric repeats and fused with any of numerous fluorescent proteins (FPs). TALE-telomere-FP fusion proteins were used to detect telomeric sequence in both living cells and fixed cells. Using human cells with different average telomere lengths, TALEColor signals correlated positively with telomere length. TALEs were also designed to detect centromeric sequences unique to specific chromosomes, enabling localization of these specific human chromosomes in live cells. These methods may have significant potential both for basic chromosome and genome research as well as in clinical applications. 

Back To Top 



Title: Extensible and Elastomeric Electrospun Composites with High Mineral Content. UMMS12-80; Patent Pending. 

  • This invention provides novel compositions of hydroxyapatite and block copolymers, wherein the co-polymers have degradable hydrophobic blocks and hydrophilic blocks for stable interfacing with hydroxyapatite, resulting in stable polymer-hydroxyapatite suspensions. The super- hydrophilicity, strengthened mechanical integrity, and retained structural integrity of the HA- PELA composite in aqueous environment represent major advantages over the HA-PLA composites for skeletal tissue engineering applications.

Title: Zebrafish Fli1b Rabbit Polyclonal Antibody. UMMS12-60. 

  • Rabbit polyclonal antibody that recognizes the amino terminal half of zebrafish Fli 1b, and Ets family transcription factor. 

Title: Zebrafish Etv2 Rabbit Polyclonal Antibody. UMMS12-59. 

  • Rabbit polyclonal antibody that recognizes the amino terminal half of zebrafish ETV2, a transcription factor that is essential for vascular development in all vertebrates. Etv2 is also knows as ER71, Etsrp, or Ets 1b protein.

Title: A Polyclonal Antibody that Recognizes the Zebrafish Homolog of Flt4 (zfFlt4). UMMS12-58.

  • Rabbit polyclonal antibody that recognizes zebra fish FLT4, also knows as vascular endothelial growth factor receptor-3 (VEGFR-3) is available for licensing.

Title: Rabbit & Guinea Pig Polyclonal Antibodies to the Circadian Proteins; NPAS2/MOP4, BMAL1/Arnt3/Arnt1/Mop3, Per2, CLOCK, PER1, Casein Kinase 1 delta, and Casein Kinase 1 epsilon. UMMS12-49.

  • Rabbit and Guinea Pig polyclonal antibodies to circadian protein available for licensing.
    1. anti-NPAS2: antigen is amino acids 597-916
    2. anti-BMAL1: antigen is amino acids 382-586
    3. anti-PER2: antigen is amino acids 1-200
    4. anti-CLOCK: antigen is amino acids 363-855
    5. anti-PER1: antigen is amino acids 1-23
    6. anti-CASEIN KINASE 1 DELTA: antigen is amino acids 243-415
    7. anti-CASEIN KINASE 1 EPSILON: antigen is residues 202-416

Title: Zwitterionic Ligands for Templated Mineralization. UMMS12-36; Patent Pending. 

  • The invention provides novel compositions and methods for three-dimensional mineralization templated by synthetic scaffolds having zwitterionic mediators. The invention enables 3-D mineralization nucleation and growth of minerals in a well-controlled and defined manner. The composite materials prepared by the disclosed methods are cytocompatible and/or biodegradable and are suitable for use as medical implants in a variety of applications in skeletal tissue repair and regeneration.


  • To better understand the risks associated with stem cell therapies, this invention provides compounds to track transplanted stem cells in vivo overtime using noninvasive imaging techniques.  Specifically, the invention provides novel multi-modality probes constructed by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging.

Title: An IFNβ Reporter Cell Line, clone SZ34. UMMS12-01. 

  • Large-scale and high throughput screen for compounds that module type I interferons identify potential therapeutics that block viral replication. Clone SZ34 is a stabilly transfected human embryonic kidney cell (HEK) with expression plasmids for an IFN-Beta-promoter-driven firefly luciferase reporter gene (IFN-Beta-Luc).

Back To Top



Title: anti-OC-STAMP Antibody. UMMS11-56.  

  • Chicken polyclonal antibody that recognizes OC-STAMP is available for licensing.  Antigen is human OC-STAMP amino acids 141-161, the extracellular domain. OC-STAMP plays a role in osteoclast fusion and bone formation.

Title: MUTANT LUCIFERASES. UMMS11-28; Patent 9,587,266. 

  • This technology provides novel mutant luciferases capable of efficient light emission with aminoluciferins that can be used to monitor gene expression in mammalian cells or perform bioluminescence imaging in whole organisms. This technology is based on the finding that the disclosed genetically-modified luciferases give higher light output in live mammalian cells than D-luciferin over a wide concentration range.

Title: The Use of the Salmonella Typhimurium Protein, SipA, as Multidrug Resistance (MDR) Reversal Agent. UMMS11-17; Patent Pending. 

  • The invention provides compositions and methods to revert multi-drug resistance in human cancers by inhibiting P-gp and/or p53 with purified SipA.

Title: Activated p38 MAPK Isolated From Bacterial Cell Culture. UMMS11-06.

  • DE3 E-coli cells that express a his-tagged p38 MAPK construct yielding phosphorylated p38 MAPK without the secondary step of treating with MKK6.

Back To Top 



Title: Transgenic Non-Human Animal and Methods for Stem Cell Engraftment. UMMS10-43; Patent Pending. 

  • A transgenic immunodeficient non-obese diabetic (NOD) mouse homozygous for the SCID mutation and having an IL2 receptor gamma chain deficiency. Administration of human stem cells to the mouse in the absence of conditioning by irradiation results in similar or greater levels of engraftment of human stem cells compared to a non-obese diabetic (NOD) mouse homozygous. 


  • The present invention improves upon previously described yeast-based microencapsulation methodologies, in particular, by providing for the incorporation of nanoparticles into and/or onto yeast cell wall particles (YCWPs), for example, yeast glucan particles (microparticles) (YGPs). The improved technologies provide for delivery of nanoparticles, the nanoparticles themselves having utility in biomedical applications, or the nanoparticles imparting one or more functionalities of use in various biomedical, e.g., drug delivery applications. 

Back To Top




  • This invention discloses methods and compositions to detect Toll-like receptor (TLR) binding to ligands and evaluate compound for screening. Using different biosensor complexes, this technology enables the diagnosis of gram positive or negative infections in a human subject. Each platform utilizes a TLR conjugated to a biosensor that detects a single TLR-ligand binding domain complementary to its cognate ligand. This technology can provide a method to select appropriate treatment for a patient with inflammatory and possibly other conditions.

Title: my5C Software. UMMS09-57; Patent Pending. 

  • My5c software is a publicly available computational tool that can be used for 5C-based chromosome structural studies. 5C is a powerful high-throughput method for analyzing chromosome folding. Researchers can upload data obtained from their experiments, either by sequencing or microarray. Using My5C, researchers can obtain a two-dimensional heat map of three-dimensional chromosome structure.

Title: COMPOUNDS FOR MODULATING TLR2. UMMS09-52 Patent 8,609,6639,271,972.

  • Viral infection causes damage to the host via stimulation of production of host cytokines. These processes can culminate in edema and damage to host organs. From screening, this novel invention identifies molecules that could potentially inhibit the cytokine response to viral infection by inhibiting RNA virus-mediated TNF-alpha production. The current invention discloses methods of the system used to screen, a TLR2 and CD14 stable cell line, and molecular inhibitors of Lymphocytic Choriomeningitis Virus (LCMV) induced cytokine production. These newly discovered molecules may facilitate amelioration of symptoms in a broad range of hemorrhagic fever viruses.

Title: SPECT CAMERA. UMMS09-48; Patent 8,519,351.

  • Systems and methods for providing improved detectors for use in SPECT cameras. The improved detectors use pinhole apertures and non-planar surfaces calculated to provide improved sensitivity and resolution.


  • This invention discloses a method for studying mRNA sequences without disrupting transcript connectivity or relative abundance. Contrary to existing methods to study mRNA splicing, this method directly assesses the relative abundance of isoforms, with information regarding multiple ligases and mRNA exon connectivity. Improved understanding of isoforms may facilitate further study of developmental disease or cancer.

Back To Top 



Title: Monoclonal Antibody Producing Cell Lines called 2C3-like Cell Lines and the 2C3-like Antibodies that They Produce. UMMS08-34; Patent Pending.

  • This new invention spans from the discovery of novel antibodies and an antigen binding fragment that bind surface membrane proteins of Neisseria species (e.g. N. gonorrhoeae and N. meningitidis). This invention can be applied to diagnostic, therapeutic, and potentially preventative methods for managing Neisseria infections. 

Title: Rabbit Polyclonal Antibody to mPer1. UMMS08-33.

Title: Rabbit Polyclonal Antibody to Per2. UMMS08-32.

Title: Guinea Pig Polyclonal Antibody to BMAL. UMMS08-31.

Title: Rabbit Polyclonal Antibody to CLOCK. UMMS08-30.  

Title: Pericentrin Antibody A102. UMMS08-20.

  • Monoclonal antibody against tyrosine phosphorylated pericertrin (A012), a centrosome protein involved in microtubule organization and cell division cycle regulation. Rabbit pericentrin antibody included.

Title: New Monoclonal Peptide Antibodies to Centriolin. UMMS08-19.

  • Polyclonal peptide antibodies against Centriolin, a centrosome protein involved in microtubule organization and cell division cycle regulation. Rabbit Centriolin N-terminus and C-terminus antibodies are included.


  • This new invention predicates on the finding that midbody (MB), a singular organelle formed between daughter cells during cytokinesis required for separation, are inherited asymeetrically by daughter cell of stem cells and cancer ‘stem cells’. The new methods disclosed in this invention can modulate degradation.